NaxSwab OTC novel naloxone nasal swab successfully administered by children and adults to potentially rescue someone from an opioid overdose in study
BETHESDA, Md., April 13, 2023. Pocket Naloxone Corp., a startup pharmaceutical company with the vision of enhancing naloxone delivery, announced results from a human factors validation study, using the intend-to-market packaging and labeling,... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - April 13, 2023 Category: Pharmaceuticals Source Type: clinical trials
Clinical Outcomes From Nalmefene
Condition: Opioid Overdose Interventions: Drug: Nalmefene Hydrochloride Injection; Drug: Naloxone Hydrochloride Injection Sponsor: Purdue Pharma LP Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 12, 2023 Category: Research Source Type: clinical trials
Smartphone intervention to optimize medication-assisted treatment outcomes for opioid use disorder: study protocol for a randomized controlled trial
This study will test if adjunctive use of OptiMAT improve MOUD outcomes. Study findings could lead to expansion of OptiMAT into rural clinical settings, and the identification of OptiMAT features which best predict positive clinical outcome could lead to refinement of this and similar smartphone app-based interventions.Trial registration
ClinicalTrials.gov
identifier:NCT05336188, registered March 21, 2022. (Source: Trials)
Source: Trials - April 4, 2023 Category: Research Source Type: clinical trials
Permanent Supportive Housing Overdose Prevention
Condition: Overdose Intervention: Behavioral: CSH-Delivered Overdose Prevention Support Sponsors: NYU Langone Health; National Institute on Drug Abuse (NIDA) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 27, 2023 Category: Research Source Type: clinical trials
